PODCAST: The importance of treating the constellation of major depressive disorder symptoms
Listen to Prof. Malcolm Hopwood, the Ramsay Health Care Professor of Psychiatry, University of Melbourne speak to Prof. John Tiller, University of Melbourne and Albert Road Clinic, Melbourne, about the importance of treating the constellation of major depressive disorder symptoms.
QUALIFIERS
P values for comparative studies mentioned in this interview
AtWoRC: Open-label study of patients with MDD treated with vortioxetine. The primary endpoint was the correlation between changes in PDQ-D-20 (Perceived Deficits Questionnaire) and WLQ (Work Limitations Questionnaire) at week 12(p< 0.001). Secondary endpoints included mean change from baseline to week 12 in cognitive measures (DSST, PDQ-D-20), p<0.0001.6
The incidence of sexual dysfunction was similar to placebo for Brintellix 5–10 mg. At 15–20 mg, the incidence of sexual dysfunction increases.8
The majority of cases of nausea in the MDD Short-Term studies were transient and mild to moderate and did not generally lead to cessation of therapy.8
Improvements in SHAPS (p < 0.0001) and MADRS anhedonia factors (p < 0.0001), between baseline and 8 week endpoint in patients with MDD (post-hoc analysis).11
